Loading...
•
Sep 30, 2020
Innoviva Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Innoviva reported an increase in RELVAR®/BREO® ELLIPTA® global net sales by 38% compared to the third quarter of 2019 and TRELEGY® ELLIPTA® global net sales were $251.9 million, compared to $172.8 million during the comparable period a year ago.
RELVAR®/BREO® ELLIPTA® global net sales increased by 38% compared to Q3 2019.
U.S. net sales of RELVAR®/BREO® ELLIPTA® increased by 79% due to a significant prior period adjustment from favorable pricing and continued volume growth.
TRELEGY® ELLIPTA® global net sales were $251.9 million, compared to $172.8 million during the comparable period a year ago.
ANORO® ELLIPTA® global net sales increased by 3% in Q3 2020 compared to the same quarter of 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...